News

Virginia Tech Corporate Research Center selected to lead innovative new lab space model in SWVA

The Virginia Tech Corporate Research Center (VTCRC) in partnership with the Virginia Tech Foundation (VTF) has been awarded a grant from the GO Virginia program to fund the evaluation and design of new lab concepts to serve southwest Virginia’s growing life and health sciences industry. The award is part of the Enhanced Capacity Building program that will support Virginia’s Region 2.

“We’re honored to be selected to lead this project. The VTCRC is dedicated to making flexible lab space more accessible for smaller startups as well as some of our high-growth companies. This effort will lead to much-needed resources that will help us grow our biotech industry, recruit new companies, and create valuable jobs for our local economy,” said Brett Malone, Ph.D., CEO of the VTCRC.

VTCRC is committed to creating opportunity for growth in Region 2 by leading the design and development of creative lab facilities. The goal is to build on Virginia Tech’s growing presence in the Roanoke Innovation Corridor and in Montgomery County at the VTCRC. This project will be spearheaded by the VTCRC and will include input and guidance from all relevant stakeholders in the region, including Montgomery County, City of Roanoke, Valleys Innovation Council (VIC), RAMP, Roanoke Blacksburg Technology Council (RBTC), Fralin Biomedical Research Institute at VTC, Onward NRV, New River Valley Regional Commission, Roanoke Regional Partnership, and Link License Launch from Virginia Tech.

VTCRC will lead development of a comprehensive assessment, conceptual design, and associated operational plan to support both Roanoke and Blacksburg’s life and health sciences ecosystem with flexible laboratory space. The scope of the project is to assess the demand and projected growth in need for lab space in Region 2, create a working plan to serve the entire region, and create an initial conceptual design with associated presentation materials to drive investor and market interest. The VTCRC plans to address the needs of functional lab space, recruiting new companies, and retaining talent in the area.

“The impact of the project will be far-ranging and could ultimately lead to 800-1,000 new jobs, helping to retain talent in the region. The life sciences sector in Region 2 is vibrant and expanding, and this project will work to provide a necessity for both existing and emerging biotech companies,” said Raymond Smoot, Chair of the GO Virginia Region 2 Council.

“We are very excited to see this project be launched,” said Michael Friedlander, Virginia Tech’s Vice President for Health Sciences and Technology and director of the Fralin Biomedical Research Institute at VTC. “The development of a facility to allow our entrepreneurial biomedical researchers access to launch their startup companies has always been a key part of the biomedical discovery and implementation vision for Roanoke. Moreover, as the translational research enterprise has grown over the last decade, we increasingly encounter outside companies who express interest a presence on the health sciences campus to have the opportunity to interact with the scientists at the research institute. The GO Virginia grant will allow for a systematic and comprehensive analysis of the needs and opportunities for advancing the health sciences translational ecosystem here in Roanoke – it’s an important next step.”

Once the feasibility project is complete, The VTCRC will review and plan for next steps.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by